Astrazeneca (AZN) Operating Income (2016 - 2026)

Astrazeneca has reported Operating Income over the past 16 years, most recently at $4.2 billion for Q1 2026.

For Q1 2026, Operating Income rose 15.57% year-over-year to $4.2 billion; the TTM value through Mar 2026 reached $14.3 billion, up 35.53%, while the annual FY2025 figure was $13.7 billion, 37.39% up from the prior year.
Operating Income for Q1 2026 was $4.2 billion at Astrazeneca, up from $3.0 billion in the prior quarter.
Over five years, Operating Income peaked at $4.2 billion in Q1 2026 and troughed at $539.0 million in Q2 2022.
A 5-year average of $2.3 billion and a median of $2.5 billion in 2023 define the central range for Operating Income.
On a YoY basis, Operating Income climbed as much as 474.66% in 2022 and fell as far as 52.17% in 2022.
Year by year, Operating Income stood at $1.1 billion in 2022, then rose by 12.8% to $1.2 billion in 2023, then skyrocketed by 64.99% to $2.0 billion in 2024, then surged by 46.27% to $3.0 billion in 2025, then soared by 42.58% to $4.2 billion in 2026.
Business Quant data shows Operating Income for AZN at $4.2 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.6 billion in Q3 2025.

Peer Comparison